AI-Powered Liver Cancer Research

HCC is the most common primary liver cancer, often arising from cirrhosis or viral hepatitis. AI agents research immune checkpoint combinations, TKIs, and locoregional approaches.

Standard of Care

Atezolizumab + bevacizumab (1st line), sorafenib/lenvatinib, TACE, Y-90 radioembolization, liver transplant (selected cases).

Prevalence

~41,000 new liver cancer diagnoses per year in the US.

Five-Year Survival

Stage IV: ~3%. With immunotherapy combination: median survival ~19 months.

Key Mutations

• TP53
• CTNNB1 (β-catenin)
• TERT promoter
• ARID1A
• FGF19 amplification

Key Pathways

• vegf-angiogenesis
• wnt-beta-catenin
• pd-1-pd-l1
• fgf-signaling

Clinical Trial Focus

Tremelimumab + durvalumab (STRIDE), GPC3-targeted CAR-T, oncolytic viruses, FGFR inhibitors.